Comorbidities in Australian women with hormone-dependent breast cancer: A population-based analysis

Huah Shin Ng, Bogda Koczwara, David Roder, Theo Niyonsenga, Agnes I. Vitry

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To compare how frequently selected chronic diseases developed in women with breast cancer receiving endocrine therapy, and in women without cancer. Design, setting and participants: Retrospective, rolling cohort study, analysing a random 10% sample of Pharmaceutical Benefits Scheme (PBS) data for the period 1 January 2003 e 31 December 2014. Women with breast cancer who first commenced endocrine therapy between January 2004 and December 2011 were identified, and age- and sex-matched (1:10) by comorbidity with control groups of women who did not have a dispensing record for antineoplastic agents during the study period or the comorbidity of interest at baseline. Main outcome measures: Development of any of eight preselected comorbidities, identified in PBS claims data with the RxRisk-V model. Results: Women with hormone-dependent breast cancer were significantly more likely than women in the control group to develop depression (overall hazard ratio [HR], 1.36; 95% CI, 1.26-1.46), pain or paineinflammation (HR, 1.30; 95% CI, 1.23-1.38), osteoporosis (overall HR, 1.27; 95% CI, 1.17-1.39), diabetes (HR, 1.24; 95% CI, 1.10-1.41), cardiovascular disorders (overall HR, 1.22; 95% CI, 1.13-1.32), and gastric acid disorders (HR, 1.20; 95% CI, 1.13-1.28). The hazard ratios for developing cardiovascular disorders, depression and osteoporosis were highest during the first year of endocrine therapy. The risk of hyperlipidaemia was lower among women with breast cancer than in the control group (HR, 0.88; 95% CI, 0.81-0.96). There was no significant difference between the two groups in the risk of reactive airway diseases (HR, 1.05; 95% CI, 0.98-1.13). Conclusion: Comorbid conditions are more likely to develop in women who have been diagnosed with hormone-dependent breast cancer than in women without cancer. Our results further support the need to develop appropriate models of care to manage the multiple chronic disorders of breast cancer survivors.

LanguageEnglish
Pages24-28
Number of pages5
JournalMedical Journal of Australia
Volume208
Issue number1
DOIs
Publication statusPublished - 15 Jan 2018

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{146ad8acaf7a48b9ab487161ebc5f10d,
title = "Comorbidities in Australian women with hormone-dependent breast cancer: A population-based analysis",
abstract = "Objective: To compare how frequently selected chronic diseases developed in women with breast cancer receiving endocrine therapy, and in women without cancer. Design, setting and participants: Retrospective, rolling cohort study, analysing a random 10{\%} sample of Pharmaceutical Benefits Scheme (PBS) data for the period 1 January 2003 e 31 December 2014. Women with breast cancer who first commenced endocrine therapy between January 2004 and December 2011 were identified, and age- and sex-matched (1:10) by comorbidity with control groups of women who did not have a dispensing record for antineoplastic agents during the study period or the comorbidity of interest at baseline. Main outcome measures: Development of any of eight preselected comorbidities, identified in PBS claims data with the RxRisk-V model. Results: Women with hormone-dependent breast cancer were significantly more likely than women in the control group to develop depression (overall hazard ratio [HR], 1.36; 95{\%} CI, 1.26-1.46), pain or paineinflammation (HR, 1.30; 95{\%} CI, 1.23-1.38), osteoporosis (overall HR, 1.27; 95{\%} CI, 1.17-1.39), diabetes (HR, 1.24; 95{\%} CI, 1.10-1.41), cardiovascular disorders (overall HR, 1.22; 95{\%} CI, 1.13-1.32), and gastric acid disorders (HR, 1.20; 95{\%} CI, 1.13-1.28). The hazard ratios for developing cardiovascular disorders, depression and osteoporosis were highest during the first year of endocrine therapy. The risk of hyperlipidaemia was lower among women with breast cancer than in the control group (HR, 0.88; 95{\%} CI, 0.81-0.96). There was no significant difference between the two groups in the risk of reactive airway diseases (HR, 1.05; 95{\%} CI, 0.98-1.13). Conclusion: Comorbid conditions are more likely to develop in women who have been diagnosed with hormone-dependent breast cancer than in women without cancer. Our results further support the need to develop appropriate models of care to manage the multiple chronic disorders of breast cancer survivors.",
author = "Ng, {Huah Shin} and Bogda Koczwara and David Roder and Theo Niyonsenga and Vitry, {Agnes I.}",
year = "2018",
month = "1",
day = "15",
doi = "10.5694/mja17.00006",
language = "English",
volume = "208",
pages = "24--28",
journal = "The Medical journal of Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "1",

}

Comorbidities in Australian women with hormone-dependent breast cancer : A population-based analysis. / Ng, Huah Shin; Koczwara, Bogda; Roder, David; Niyonsenga, Theo; Vitry, Agnes I.

In: Medical Journal of Australia, Vol. 208, No. 1, 15.01.2018, p. 24-28.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comorbidities in Australian women with hormone-dependent breast cancer

T2 - The Medical journal of Australia

AU - Ng, Huah Shin

AU - Koczwara, Bogda

AU - Roder, David

AU - Niyonsenga, Theo

AU - Vitry, Agnes I.

PY - 2018/1/15

Y1 - 2018/1/15

N2 - Objective: To compare how frequently selected chronic diseases developed in women with breast cancer receiving endocrine therapy, and in women without cancer. Design, setting and participants: Retrospective, rolling cohort study, analysing a random 10% sample of Pharmaceutical Benefits Scheme (PBS) data for the period 1 January 2003 e 31 December 2014. Women with breast cancer who first commenced endocrine therapy between January 2004 and December 2011 were identified, and age- and sex-matched (1:10) by comorbidity with control groups of women who did not have a dispensing record for antineoplastic agents during the study period or the comorbidity of interest at baseline. Main outcome measures: Development of any of eight preselected comorbidities, identified in PBS claims data with the RxRisk-V model. Results: Women with hormone-dependent breast cancer were significantly more likely than women in the control group to develop depression (overall hazard ratio [HR], 1.36; 95% CI, 1.26-1.46), pain or paineinflammation (HR, 1.30; 95% CI, 1.23-1.38), osteoporosis (overall HR, 1.27; 95% CI, 1.17-1.39), diabetes (HR, 1.24; 95% CI, 1.10-1.41), cardiovascular disorders (overall HR, 1.22; 95% CI, 1.13-1.32), and gastric acid disorders (HR, 1.20; 95% CI, 1.13-1.28). The hazard ratios for developing cardiovascular disorders, depression and osteoporosis were highest during the first year of endocrine therapy. The risk of hyperlipidaemia was lower among women with breast cancer than in the control group (HR, 0.88; 95% CI, 0.81-0.96). There was no significant difference between the two groups in the risk of reactive airway diseases (HR, 1.05; 95% CI, 0.98-1.13). Conclusion: Comorbid conditions are more likely to develop in women who have been diagnosed with hormone-dependent breast cancer than in women without cancer. Our results further support the need to develop appropriate models of care to manage the multiple chronic disorders of breast cancer survivors.

AB - Objective: To compare how frequently selected chronic diseases developed in women with breast cancer receiving endocrine therapy, and in women without cancer. Design, setting and participants: Retrospective, rolling cohort study, analysing a random 10% sample of Pharmaceutical Benefits Scheme (PBS) data for the period 1 January 2003 e 31 December 2014. Women with breast cancer who first commenced endocrine therapy between January 2004 and December 2011 were identified, and age- and sex-matched (1:10) by comorbidity with control groups of women who did not have a dispensing record for antineoplastic agents during the study period or the comorbidity of interest at baseline. Main outcome measures: Development of any of eight preselected comorbidities, identified in PBS claims data with the RxRisk-V model. Results: Women with hormone-dependent breast cancer were significantly more likely than women in the control group to develop depression (overall hazard ratio [HR], 1.36; 95% CI, 1.26-1.46), pain or paineinflammation (HR, 1.30; 95% CI, 1.23-1.38), osteoporosis (overall HR, 1.27; 95% CI, 1.17-1.39), diabetes (HR, 1.24; 95% CI, 1.10-1.41), cardiovascular disorders (overall HR, 1.22; 95% CI, 1.13-1.32), and gastric acid disorders (HR, 1.20; 95% CI, 1.13-1.28). The hazard ratios for developing cardiovascular disorders, depression and osteoporosis were highest during the first year of endocrine therapy. The risk of hyperlipidaemia was lower among women with breast cancer than in the control group (HR, 0.88; 95% CI, 0.81-0.96). There was no significant difference between the two groups in the risk of reactive airway diseases (HR, 1.05; 95% CI, 0.98-1.13). Conclusion: Comorbid conditions are more likely to develop in women who have been diagnosed with hormone-dependent breast cancer than in women without cancer. Our results further support the need to develop appropriate models of care to manage the multiple chronic disorders of breast cancer survivors.

UR - http://www.scopus.com/inward/record.url?scp=85041136330&partnerID=8YFLogxK

U2 - 10.5694/mja17.00006

DO - 10.5694/mja17.00006

M3 - Article

VL - 208

SP - 24

EP - 28

JO - The Medical journal of Australia

JF - The Medical journal of Australia

SN - 0025-729X

IS - 1

ER -